Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication

Psychiatry Research

Volumn 169, Issue 1, 2009, Pages 51-55

  Halacheva, Krasimira ^a   Dimova, Svetlana ^a   Tolev, Todor ^b   Dimov, Dimo ^b   Nikolova, Maria ^b  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b State Psychiatric Hospital D r G Kisjov   (Bulgaria)

Author keywords

Anticardiolipin antibodies; Autoimmunity; Psychotic symptoms; Schizophrenia

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUROLEPTIC AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; VOLUNTEER;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPSYCHOTIC AGENTS; CARDIOLIPINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS;

EID: 67651166588     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.05.011     Document Type: Article

References (38)

1. Cabral A.R., Cabiedes J., and Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein I than with antiphospholipid antibodies. Journal of Rheumatology 22 (1995) 1899-1906
2. Canoso R.T., Oliveira R.M., and Nixon R.A. Neuroleptic associated autoantibodies. A prevalence study. Biological Psychiatry 27 (1990) 863-870
3. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., Jacobsen S., Lakos G., Tincani A., Kontopoulou-Griva I., Galeazzi M., Meroni P.L., Derksen R.H., de Groot P.G., Gromnica-Ihle E., Baleva M., Mosca M., Bombardieri S., Houssiau F., Gris J.C., Quere I., Hachulla E., Vasconcelos C., Roch B., Fernandez-Nebro A., Boffa M.C., Hughes G.R., Ingelmo M., and Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis and Rheumatism 46 4 (2002) 1019-1027
4. Chengappa K.N., Carpenter A.B., Keshavan M.S., Yang Z.W., Kelly R.H., Rabin B.S., and Ganguli R. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biological Psychiatry 30 (1991) 731-735
5. Firer M., Sirota P., Schild K., Elizur A., and Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. Journal of Clinical Immunology 14 1 (1994) 73-78
6. Galli M., Comfurius P., Maassen C., Hemker H.C., De Baets M.H., Van Breda-Vriesman P.J.C., Barbui T., Zwaal R.F.A., and Bevers E.M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335 (1990) 1544-1547
7. Ganguli R., Rabin B.S., and Brar J.S. Antinuclear and gastric parietal cell antibodies in schizophrenic patients. Biological Psychiatry 32 (1992) 735-738
8. Gastineau D.A., Kazmier F.J., Nichols W.L., and Bowie E.J. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. American Journal Hematology 19 (1985) 265-275
9. Henneberg A.E., Horter S., and Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophrenia Research 14 (1994) 15-22
10. Hunt J.E., McNeil H.P., Morgan G.J., Crameri R.M., and Krilis S.A. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1 (1992) 83-90
11. Jones A.L., Mowry B.J., Pender M.P., and Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunology and Cell Biology 83 (2005) 9-17
12. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 2 (1987) 261-276
13. Keshavan M.S., Pettegren J.W., and Panchalingam K. In vivo 31P nuclear magnetic resonance (NMR) spectroscopy of the frontal lobe metabolism in neuroleptic-naïve first episode psychoses. Preliminary studies. Schizophrenia Research 2 (1989) 122 (abstr)
14. Koike T., and Matsuura E. What is the "true" antigen for anticardiolipin antibodies. Lancet 337 (1991) 671-672
15. Koerschenhausen D., Hampel H., Ackenheil M., Penning R., and Mueller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophrenia Research 19 (1996) 103-109
16. Lin A., Kenis G., Bignoti S., Tura G.J.B., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., and Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum Interleukin-6. Schizophrenia Research 32 (1998) 9-15
17. Maes M., Meltzer H.Y., and Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89 (1994) 346-351
18. Maes M., Bosmans E., Calabrese J., Smith R., and Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood-stabilizers. Journal of Psychiatric Research 29 (1995) 141-152
19. Matsuura E., Igarashi Y., Fugimot M., Ichikawa K., Suzuki T., Sumida T., Yasuda T., and Koike T. Heterogeinity of anticardiolipin antibodies defined by the anti-cardiolipin cofactor. Journal of Immunology 148 (1992) 3885-3891
20. Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., and Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen-modified solid phase surface. Journal of Experimental Medicine 179 (1994) 457-462
21. McNally T., Purdy G., Mackie I.J., Machin S.G., and Isenberg D.A. The use of an β2-glycoprotein I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. British Journal of Haematology 91 (1995) 471-473
22. McNeil H.P., Simpson R.J., Chesterman C.N., and Krilis S.A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2 glycoprotein I (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 4120-4124
23. Pengo V., Biasiolo A., and Fior M.G. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thrombosis and Haemostasis 73 (1995) 29-34
24. Rothermundt M., Arolt V., and Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain, Behavior, and Immunity 15 (2001) 319-339
25. Rotrosen J., and Nolkin A. Phospholipid and prostaglandin hypothesis in schizophrenia. In: Meltzer H.V. (Ed). Psychopharmacology: The Third Generation in Progress (1987), Raven Press, New York 759
26. Roubey R.A.S., Maldonado M.A., and Byrd S.N. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis and Rheumatism 36 (1996) 1606-1607
27. Sammaritano L.R., Gharavi A.G., and Lockshin M.D. Antiphospholipid syndrome: immunological and clinical aspects. Seminars in Arthritis and Rheumatism 20 (1990) 81-88
28. Schwarz M.J., Chiang S., Mueller N., and Ackenheil M. Th1 and Th2 responses in psychiatric disorders. Brain, Behavior, and Immunity 15 (2001) 340-370
29. Schwarz M.J., Mueller N., Riedel M., and Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Medical Hypotheses 56 (2001) 483-489
30. Sirota P., Bogdanov I., Katzav A., Hershko R., and Chapman J. Reduced anticardiolipin antibodies in first episode and chronic schizophrenia. Psychiatry Research 144 (2006) 211-216
31. Sperner-Unterweger B., Miller C., Holzner B., Widner B., Fleischhacker W.W., and Fuchs D. Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Mueller N. (Ed). Psychiatry, Psychoimmunology, and Viruses (1999), Springer Wien, NY 115-119
32. Spivak B., Radwan M., Bartur P., Mester R., and Weizman A. Antinuclear antibodies in chronic schizophrenia. Acta Psychiatrica Scandinavica 92 4 (1995) 266-269
33. Sundin U., and Thelander S. Antibody reactivity to brain membrane proteins in serum from schizophrenic patients. Brain, Behavior, and Immunity 3 (1989) 345-358
34. White L., Harvey P.D., Opler L., and Lindenmayer J.P. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30 5 (1997) 263-274
35. Wilke I., Arolt W., Rotermundt M., Weitzsch Ch., Hornberg M., and Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Archives of Psychiatry and Clinical Neurosciences 246 (1996) 279-284
36. Yang Z.W., Chengappa K.N., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., and Ganguli R. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychological Medicine 24 2 (1994) 449-455
37. Yannitsi S.G., Manoussakis M.N., and Mauridis A.K. Factors related to the presence of autoantibodies in patients with chronic mental disorders. Biological Psychiatry 27 (1990) 747-756
38. Zorrilla E.P., Cannon T.D., Gur R.E., and Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability of disease?. Biological Psychiatry 40 (1996) 825-833